InBios International, Inc.
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
Role: collaborator
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
Role: lead
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
Role: lead
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
Role: lead
Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
Role: lead
Specificity Study of Diagnostic for Early Detection of Dengue Infection
Role: lead
Specificity Study of Diagnostic for Chagas Disease
Role: lead
Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia
Role: collaborator
Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy
Role: collaborator
Sensitivity Study of Diagnostic for Detection of Chagas Infection
Role: lead
All 10 trials loaded